Given cisplatin’s dual impact as both an antitumor agent and a nephrotoxin, understanding SH3YL1’s behavior in bladder cancer patients undergoing cisplatin therapy could reveal its potential as a biomarker for both tumor progression and renal injury. Here, SH3YL1 is linked to urinary bladder cancer.